Cellosaurus logo
expasy logo

Cellosaurus RC (CVCL_9U45)

[Text version]
Cell line name RC
Accession CVCL_9U45
Resource Identification Initiative To cite this cell line use: RC (RRID:CVCL_9U45)
Comments Doubling time: ~4-5 days (PubMed=26515759).
Miscellaneous: STR profile in PubMed=26515759 table 3 is erroneous; correct STR profile obtained by personal communication of Pham, Lan V.
Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
Disease High grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements (NCIt: C125904)
High grade B-cell lymphoma with MYC and/or BCL2 and/or BCL6 rearrangement (ORDO: Orphanet_480541)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 71Y
Category Cancer cell line
STR profile Source(s): ATCC=CRL-3382; PubMed=26515759

Markers:
AmelogeninX
CSF1PO10,12
D3S135817,19
D5S81812,13
D7S82010,13
D8S117913,15
D13S3179,11
D16S5398,12
D18S5117
D21S1128,30
FGA19,21
TH016
TPOX8
vWA15,18

Run an STR similarity search on this cell line
Publications

PubMed=20664054; DOI=10.1182/blood-2009-12-257378; PMCID=PMC2981542
Pham L.V., Tamayo A.T., Li C.-P., Bueso-Ramos C.E., Ford R.J. Jr.
An epigenetic chromatin remodeling role for NFATc1 in transcriptional regulation of growth and survival genes in diffuse large B-cell lymphomas.
Blood 116:3899-3906(2010)

PubMed=26515759; DOI=10.1186/s13045-015-0218-1; PMCID=PMC4627381
Pham L.V., Lu G., Tamayo A.T., Chen J., Challagundla P., Jorgensen J.L., Medeiros L.J., Ford R.J. Jr.
Establishment and characterization of a novel MYC/BCL2 'double-hit' diffuse large B cell lymphoma cell line, RC.
J. Hematol. Oncol. 8:121.1-121.11(2015)

PubMed=29416618; DOI=10.18632/oncotarget.20378; PMCID=PMC5787470
Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C., Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr., Pham L.V.
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Oncotarget 9:346-360(2018)

PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004
Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H., Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Clin. Cancer Res. 24:3967-3980(2018)

Cross-references
Cell line collections (Providers) ATCC; CRL-3382
Encyclopedic resources Wikidata; Q54949366
Entry history
Entry creation23-Feb-2016
Last entry update19-Dec-2024
Version number17